Wedbush analyst David Nierengarten raised his price target on Juno Therapeutics (NASDAQ: JUNO) to $64.00 (from $42.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE